Nonstandard and off-label therapies for psoriasis
- 31 October 2008
- journal article
- review article
- Published by Elsevier in Clinics in Dermatology
- Vol. 26 (5) , 546-553
- https://doi.org/10.1016/j.clindermatol.2007.10.023
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Actinic damage among patients with psoriasis treated by climatotherapy at the Dead SeaJournal of the American Academy of Dermatology, 2005
- Mycophenolate mofetil in patients with hepatitis C virus infectionLupus, 2005
- Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot studyJournal of the American Academy of Dermatology, 2004
- Mycophenolate Mofetil (CellCept®) for Psoriasis: A Two-Center, Prospective, Open-Label Clinical TrialJournal of Cutaneous Medicine and Surgery, 2003
- The HYDILE Trial: Efficacy and Tolerance of a Quadruple Combination of Reverse Transcriptase Inhibitors Versus the Same Regimen Plus Hydroxyurea or Hydroxyurea and Interleukin-2 in HIV-Infected Patients Failing Protease Inhibitor-Based CombinationsHIV Research & Clinical Practice, 2002
- Treatment of psoriasis. Part 2. Systemic therapiesJournal of the American Academy of Dermatology, 2001
- Colchicine in dermatologyJournal of the American Academy of Dermatology, 1998
- Systemic retinoid therapy for psoriasisJournal of the American Academy of Dermatology, 1988
- Mycophenolic acid for psoriasisJournal of the American Academy of Dermatology, 1987
- Sulphasalazine: A Review of 40 Years?? ExperienceDrugs, 1986